Turn Therapeutics (NASDAQ:TTRX) Director Purchases $33,945.92 in Stock

Turn Therapeutics Inc. (NASDAQ:TTRX) Director Arthur Golden bought 9,868 shares of Turn Therapeutics stock in a transaction dated Monday, November 24th. The stock was purchased at an average cost of $3.44 per share, for a total transaction of $33,945.92. Following the completion of the acquisition, the director directly owned 60,602 shares of the company’s stock, valued at approximately $208,470.88. The trade was a 19.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Turn Therapeutics Price Performance

Shares of TTRX stock traded down $0.20 on Tuesday, reaching $3.30. The company’s stock had a trading volume of 82,657 shares, compared to its average volume of 109,339. Turn Therapeutics Inc. has a 1 year low of $2.57 and a 1 year high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.